Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. entered into a Second Amendment to its multi-tenant space lease for its headquarters at 4040 Campbell Avenue, Menlo Park, California. The amendment, signed with Deerfield Campbell, LLC, extends the existing lease term by 26 months, starting on November 1, 2026 and ending on December 31, 2028.
Under the extension, base monthly rent is fully abated from November 1, 2026 through December 31, 2026. Rent is then set at $44,915.45 per month from January 1, 2027 through October 31, 2027, $46,214.21 per month from November 1, 2027 through October 31, 2028, and $47,621.20 per month from November 1, 2028 through December 31, 2028.
Sight Sciences, Inc. director and Chief Technology Officer David Badawi reported a small insider sale of company stock. On January 16, 2026, he sold 4,836 shares of common stock at a weighted average price of $6.62 per share to cover his tax liability in connection with the vesting of restricted stock units.
After this transaction, Badawi beneficially owns a total of 1,912,273 shares of Sight Sciences common stock, consisting of 1,774,250 shares of common stock and 138,023 shares that will be acquired upon the vesting and settlement of unvested restricted stock units.
Sight Sciences, Inc. Chief Financial Officer James Rodberg reported a small sale of company stock on January 16, 2026. He sold 2,616 shares of common stock at a weighted average price of $6.62 per share to cover his tax liability arising from the vesting of restricted stock units. The shares were sold in multiple trades at prices ranging from $6.44 to $6.69.
After this transaction, Rodberg beneficially owned 151,230 shares, consisting of 39,451 shares of common stock and 111,779 shares that will be received upon future vesting and settlement of restricted stock units.
Sight Sciences, Inc. President and CEO Paul Badawi, who is also a director and 10% owner, reported selling 22,362 shares of common stock on January 16, 2026 at a weighted average price of $6.62 per share. According to the filing, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi beneficially owns 6,025,840 shares of Sight Sciences common stock. This total includes 5,517,778 shares of common stock and 508,062 shares that will be received upon the vesting and settlement of unvested RSUs. The balance also corrects prior Form 4 reports by adding previously omitted RSUs and excluding certain stock option shares that were mistakenly included earlier.
Sight Sciences Chief Legal Officer Jeremy B. Hayden reported selling 6,308 shares of the company’s common stock on January 16, 2026 at a weighted average price of $6.62 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units, rather than as a discretionary open-market sale. Following this transaction, he beneficially owns 267,611 shares, consisting of 75,562 shares of common stock and 192,049 shares that will be received upon vesting and settlement of unvested RSUs. The filing also clarifies prior reporting by adding 39,825 previously omitted RSU shares and removing 11,326 stock option shares that had been inadvertently included in an earlier balance.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Sight Sciences, Inc. common stock. As of the event date of December 31, 2025, BlackRock reports beneficial ownership of 2,651,156 shares, representing 5.01% of Sight Sciences’ outstanding common stock.
BlackRock reports sole voting power over 2,614,209 shares and sole dispositive power over 2,651,156 shares, with no shared voting or dispositive power. The filing notes that various underlying persons have rights to dividends or sale proceeds in the ordinary course, but no single person has more than five percent of the total outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Sight Sciences, consistent with a passive institutional investment.
A shareholder has filed a Form 144 notice to sell SGHT common stock. The notice covers a proposed sale of 2,616 shares of common stock through Fidelity Brokerage Services LLC on or about 01/16/2026 on the NASDAQ market, with an aggregate market value of 17,310.86. The issuer has 52,871,731 shares of this class outstanding.
The 2,616 shares to be sold were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation. The person named, James Rodberg, has also sold common shares of the same issuer during the past three months, including 2,518 shares on 12/02/2025 for gross proceeds of 20,782.06, 4,405 shares on 01/05/2026 for 34,460.31, and 594 shares on 01/06/2026 for 4,444.07.
A shareholder of SGHT filed a Rule 144 notice to sell 4,836 shares of common stock, with an aggregate market value of $32,001.26, through Fidelity Brokerage Services on the NASDAQ around 01/16/2026. The filing indicates there were 52,871,731 common shares outstanding at the time this notice was prepared, which is a separate baseline figure.
The 4,836 shares were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/15/2026. Over the prior three months, the same seller, David Y. Badawi, reported additional common stock sales of 2,914 shares for $21,654.23, 3,051 shares for $23,867.97, and 3,695 shares for $27,644.51. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
Sight Sciences (SGHT) shareholder Paul Badawi has filed a Form 144 notice indicating an intent to sell 22,362 shares of common stock through Fidelity Brokerage Services on or about 01/16/2026 on NASDAQ, with an aggregate market value of $147,976.06 at the time of the notice. These shares were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation. The notice also reports that during the past three months, Badawi sold 25,356 common shares on 01/02/2026 for gross proceeds of $188,422.97 and 11,870 common shares on 01/06/2026 for gross proceeds of $88,806.59. Shares of common stock outstanding were 52,871,731 as of the filing, providing context for the scale of these transactions.
Sight Sciences insider transaction: A notice has been filed to sell 6,308 shares of common stock of Sight Sciences through Fidelity Brokerage Services LLC on or about 01/16/2026, with the shares listed on NASDAQ. The shares relate to restricted stock that vested on 01/15/2026, acquired from the issuer as compensation.
As context, the notice reports 52,871,731 shares of common stock outstanding. It also lists prior sales during the past three months by Jeremy Hayden, including 3,150 shares sold on 11/12/2025 for gross proceeds of 25,227.78, 44,850 shares sold on 11/25/2025 for 362,596.77, 9,385 shares sold on 01/05/2026 for 73,418.85, and 1,785 shares sold on 01/06/2026 for 13,354.66.